(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are BENEVOLENTAI, AFFLUENT MEDICAL, and ARGENX SE.

Financial Asset	Price	Change	Updated (EST)
BENEVOLENTAI (BAI.AS)	0.80	45.45%	2023-12-25 12:00:52
AFFLUENT MEDICAL (AFME.PA)	2.29	24.46%	2023-12-25 12:45:11
ARGENX SE (ARGX.BR)	336.90	12.79%	2023-12-25 12:04:40
NEXITY (NXI.PA)	17.21	10.75%	2023-12-25 13:20:41
FUT.CLUBE PORTO (FCP.LS)	1.26	9.57%	2023-12-25 12:23:10
NANOBIOTIX (NANO.PA)	5.93	7.82%	2023-12-25 13:20:32
NX FILTRATION (NXFIL.AS)	6.35	7.63%	2023-12-25 12:03:00
ALAN ALLMAN (AAA.PA)	10.60	7.07%	2023-12-25 12:45:20
CASINO GUICHARD (CO.PA)	0.71	7.05%	2023-12-25 13:00:50
GLINTT (GLINT.LS)	0.38	6.74%	2023-12-25 12:23:14

The three biggest losers today are PROSUS, NORTHERN DRILLING, and POXEL.

Financial Asset	Price	Change	Updated (EST)
PROSUS (PRX.AS)	25.63	-13.38%	2023-12-25 12:03:29
NORTHERN DRILLING (NODL.OL)	1.16	-13.11%	2023-12-25 12:41:39
POXEL (POXEL.PA)	0.58	-10.77%	2023-12-25 13:21:31
SODITECH (SEC.PA)	1.26	-10%	2023-12-25 13:22:50
FAYENC.SARREGUEMI. (FAYE.PA)	18.40	-8%	2023-12-25 13:03:13
CELYAD ONCOLOGY (CYAD.BR)	0.36	-6.22%	2023-12-25 12:05:17
GUILLEMOT (GUI.PA)	6.30	-5.83%	2023-12-25 13:04:31
BIOTALYS (BTLS.BR)	4.70	-5.62%	2023-12-25 12:05:06
SEQUANA MEDICAL (SEQUA.BR)	3.72	-5.1%	2023-12-25 12:21:21
HAVILA SHIPPING (HAVI.OL)	5.37	-4.45%	2023-12-25 12:40:24

Winners today

1. BENEVOLENTAI (BAI.AS)

45.45% Price Change

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI rising 45.45% to €0.80 on Monday while AEX-Index fell 0.56% to €785.45.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.47.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.97%.

Yearly Top and Bottom Value

BENEVOLENTAI’s stock is valued at €0.80 at 21:40 EST, way below its 52-week high of €3.76 and way higher than its 52-week low of €0.48.

More news about BENEVOLENTAI.

2. AFFLUENT MEDICAL (AFME.PA)

24.46% Price Change

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

CAC 40 ended the session with AFFLUENT MEDICAL jumping 24.46% to €2.29 on Monday while CAC 40 fell 0.03% to €7,568.82.

Earnings Per Share

As for profitability, AFFLUENT MEDICAL has a trailing twelve months EPS of €-0.65.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.36%.

Moving Average

AFFLUENT MEDICAL’s value is way above its 50-day moving average of €1.23 and way above its 200-day moving average of €1.48.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AFFLUENT MEDICAL’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth declined by 25.8%, now sitting on 1.34M for the twelve trailing months.

Yearly Top and Bottom Value

AFFLUENT MEDICAL’s stock is valued at €2.29 at 21:40 EST, way below its 52-week high of €3.28 and way above its 52-week low of €1.10.

More news about AFFLUENT MEDICAL.

3. ARGENX SE (ARGX.BR)

12.79% Price Change

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BEL 20 ended the session with ARGENX SE rising 12.79% to €336.90 on Monday while BEL 20 rose 1.66% to €3,679.69.

Earnings Per Share

As for profitability, ARGENX SE has a trailing twelve months EPS of €-3.74.

Volume

Today’s last reported volume for ARGENX SE is 140325 which is 102.27% above its average volume of 69374.

More news about ARGENX SE.

4. NEXITY (NXI.PA)

10.75% Price Change

Nexity SA operates as a real estate company in Europe and internationally. The company operates through Development, Services, and Other Activities divisions. It develops new homes and subdivisions; and new or refurbished office buildings, high-rises building, business parks, logistics facilities, retail property, hotels, and other industrial spaces. The company also provides property management services comprising rental management, sales and lettings, and condominium managing agent services, as well as manages serviced residences for students; distributes real estate products under the iSelection and PERL brands; offers insurance brokerage and asset management services; and real estate services, including rental management and property management services, consulting, and short-term rental of working spaces. In addition, it engages in the villes and projets, and pre-development urban regeneration projects; and investment activities. The company serves individual, corporate, institutional, and local authority clients. Nexity SA was founded in 1995 and is headquartered in Paris, France.

CAC 40 ended the session with NEXITY jumping 10.75% to €17.21 on Monday, after five consecutive sessions in a row of gains. CAC 40 fell 0.03% to €7,568.82, after two sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, NEXITY has a trailing twelve months EPS of €2.26.

PE Ratio

NEXITY has a trailing twelve months price to earnings ratio of 7.62. Meaning, the purchaser of the share is investing €7.62 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.59%.

Moving Average

NEXITY’s worth is way higher than its 50-day moving average of €14.03 and under its 200-day moving average of €17.47.

Yearly Top and Bottom Value

NEXITY’s stock is valued at €17.21 at 21:40 EST, way below its 52-week high of €28.54 and way higher than its 52-week low of €11.33.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NEXITY’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 5.1%, now sitting on 4.44B for the twelve trailing months.

More news about NEXITY.

5. FUT.CLUBE PORTO (FCP.LS)

9.57% Price Change

Futebol Clube do Porto – Futebol, S.A.D., together with its subsidiaries, participates in professional football competitions, and the sporting events promotion and organization in Portugal. It also engages in the image rights commercialization, sponsoring, merchandising, and products licensing activities; production, editing, and commercialization of multimedia material, as well as Internet, periodical, and non-periodical publications; and sport equipment management and exploration business, as well as insurance broking activities. In addition, the company organizes and sells travel and tour packages; and tickets and seat reservations, as well as represents travel agencies and tourism. Further, it is involved in the concept, design, development, production, direction, promotion, marketing, acquisition, exploration rights, recording, distribution, and dissemination of works and audiovisual programs, multimedia, television, video, cinema, theme, Internet, channels, tourist events, and cultural and sporting in any formats and systems. Additionally, the company manages, operates, and provides services in the areas of recording, production, and communication of audiovisual works, television shows, sounds, images, and other audiovisuals; and edits periodic publicities, books, and multimedia. It also explores for the Porto Canal cable television channel; and produces and executes advertisings, news reports, documentaries, and TV programs in video support. The company was founded in 1893 and is headquartered in Porto, Portugal.

PSI ended the session with FUT.CLUBE PORTO rising 9.57% to €1.26 on Monday while PSI jumped 0.53% to €6,422.27.

Earnings Per Share

As for profitability, FUT.CLUBE PORTO has a trailing twelve months EPS of €0.94.

PE Ratio

FUT.CLUBE PORTO has a trailing twelve months price to earnings ratio of 1.34. Meaning, the purchaser of the share is investing €1.34 for every euro of annual earnings.

More news about FUT.CLUBE PORTO.

6. NANOBIOTIX (NANO.PA)

7.82% Price Change

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

CAC 40 ended the session with NANOBIOTIX jumping 7.82% to €5.93 on Monday while CAC 40 slid 0.03% to €7,568.82.

Earnings Per Share

As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-1.68.

Revenue Growth

Year-on-year quarterly revenue growth grew by 147.8%, now sitting on 6.74M for the twelve trailing months.

Yearly Top and Bottom Value

NANOBIOTIX’s stock is valued at €5.93 at 21:40 EST, way below its 52-week high of €10.40 and way higher than its 52-week low of €1.61.

More news about NANOBIOTIX.

7. NX FILTRATION (NXFIL.AS)

7.63% Price Change

NX Filtration N.V. develops, manufactures, and sells hollow fiber membrane solutions for treating water and other liquids in the Netherlands, rest of Europe, North America, Asia, and internationally. The company offers direct nanofiltration, ultrafiltration, and microfiltration membrane modules that remove bacteria, viruses, micropollutants, color, nano plastics, and selective salts from water without pre-treatment and use of chemicals. It also provides HYDRAcap ultrafiltration modules to treat surface water, ground water, seawater, and wastewaters as primary treatment or pretreatment to reverse osmosis and nanofiltration. The company was incorporated in 2016 and is headquartered in Enschede, the Netherlands.

AEX-Index ended the session with NX FILTRATION rising 7.63% to €6.35 on Monday, after two successive sessions in a row of gains. AEX-Index slid 0.56% to €785.45, after two consecutive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, NX FILTRATION has a trailing twelve months EPS of €-0.12.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.69%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.3%, now sitting on 7.65M for the twelve trailing months.

Moving Average

NX FILTRATION’s worth is above its 50-day moving average of €6.33 and way under its 200-day moving average of €8.94.

Volume

Today’s last reported volume for NX FILTRATION is 49541 which is 153.52% above its average volume of 19541.

More news about NX FILTRATION.

8. ALAN ALLMAN (AAA.PA)

7.07% Price Change

Alan Allman Associates, together with its subsidiaries, engages in the provision of consulting services in Canada, France, Belgium, Luxembourg, Switzerland, and Singapore. The company offers technology consulting in the areas, including cybersecurity, cloud, data management, digitalization of tools and processes, etc.; strategy and management consulting comprising risk management, commercial intelligence, market finance, process management, change management, etc.; and industrial transformation consulting, such as purchasing and supply chain issues, relocation, cost reduction, project management, materials, process consulting, etc. The company was incorporated in 1954 and is based in Issy-les-Moulineaux, France.

CAC 40 ended the session with ALAN ALLMAN rising 7.07% to €10.60 on Monday, following the last session’s upward trend. CAC 40 fell 0.03% to €7,568.82, after two successive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, ALAN ALLMAN has a trailing twelve months EPS of €0.19.

PE Ratio

ALAN ALLMAN has a trailing twelve months price to earnings ratio of 55.79. Meaning, the purchaser of the share is investing €55.79 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ALAN ALLMAN’s stock is considered to be oversold (<=20).

Moving Average

ALAN ALLMAN’s worth is way above its 50-day moving average of €9.50 and higher than its 200-day moving average of €10.57.

Volatility

ALAN ALLMAN’s last week, last month’s, and last quarter’s current intraday variation average was 5.09%, 0.29%, and 2.83%.

ALAN ALLMAN’s highest amplitude of average volatility was 5.09% (last week), 3.94% (last month), and 2.83% (last quarter).

More news about ALAN ALLMAN.

9. CASINO GUICHARD (CO.PA)

7.05% Price Change

Casino, Guichard-Perrachon S.A. operates as a food retailer in France, Latin America, and internationally. The company operates hypermarkets, supermarkets, shopping malls, and e-commerce sites, as well as convenience, discount, and cash and carry stores. It also involved in banking, digital marketing, service station, franchise, real estate asset management, property development and trading, rental, banking, and energy-related activities. It operates through stores. The company was founded in 1898 and is based in Saint-Étienne, France.Casino, Guichard-Perrachon S.A operates as a subsidiary of Rallye SA.

CAC 40 ended the session with CASINO GUICHARD jumping 7.05% to €0.71 on Monday while CAC 40 dropped 0.03% to €7,568.82.

Earnings Per Share

As for profitability, CASINO GUICHARD has a trailing twelve months EPS of €-20.53.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -65.71%.

Volume

Today’s last reported volume for CASINO GUICHARD is 1118140 which is 6.04% above its average volume of 1054370.

Revenue Growth

Year-on-year quarterly revenue growth declined by 5%, now sitting on 33.42B for the twelve trailing months.

Moving Average

CASINO GUICHARD’s worth is way below its 50-day moving average of €0.86 and way under its 200-day moving average of €3.71.

More news about CASINO GUICHARD.

10. GLINTT (GLINT.LS)

6.74% Price Change

Glintt – Global Intelligent Technologies, S.A. provides IT consulting services for banking, insurance, public administration, and utilities sectors in Portugal, Spain, and Angola. It operates through two segments: Health and Other Markets. The company engages in the sale of equipment, furniture, consumables, and robotics solutions; development of architectural projects; and design and conception of lay-out and image for pharmacies, training, equipment maintenance, and consultancy projects. It licenses proprietary software solutions for healthcare providers, such as clinics, hospitals, pharmacies, and other bodies of the ministry of health; and develops, implements, and maintains software services for the health sector. In addition, the company implements ERPs, integrates internet systems, and develops tailor-made applications services. Further, the company develops, implements, and integrates partner platforms with emphasis on the BPM, ERP, BI and mobility solutions; and integrates IT infrastructures, as well as support for networking, security, storage systems, and database management. Glintt – Global Intelligent Technologies, S.A. was incorporated in 1995 and is based in Sintra, Portugal. Glintt – Global Intelligent Technologies, S.A. operates as a subsidiary of Farminveste – Investimentos, Participações E Gestão S.A.

PSI ended the session with GLINTT jumping 6.74% to €0.38 on Monday, after two sequential sessions in a row of gains. PSI rose 0.53% to €6,422.27, after two consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, GLINTT has a trailing twelve months EPS of €0.04.

PE Ratio

GLINTT has a trailing twelve months price to earnings ratio of 9.5. Meaning, the purchaser of the share is investing €9.5 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.84%.

Volume

Today’s last reported volume for GLINTT is 20566 which is 65.46% above its average volume of 12429.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jun 23, 2023, the estimated forward annual dividend rate is 0.02 and the estimated forward annual dividend yield is 5.93%.

More news about GLINTT.

Losers Today

1. PROSUS (PRX.AS)

-13.38% Price Change

Prosus N.V. engages in the e-commerce and internet businesses. The company operates internet platforms, such as classifieds, payments and fintech, food delivery, education technology, etail, health, ventures, social, and other internet platforms. It has operations in Latin and North America, the Middle East, Africa, Europe, Asia, and internationally. The company was formerly known as Myriad International Holdings N.V. and changed its name to Prosus N.V. in August 2019. Prosus N.V. was incorporated in 1994 and is headquartered in Amsterdam, the Netherlands. Prosus N.V. operates as a subsidiary of Naspers Limited.

AEX-Index ended the session with PROSUS dropping 13.38% to €25.63 on Monday, after three consecutive sessions in a row of losses. AEX-Index slid 0.56% to €785.45, after two sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, PROSUS has a trailing twelve months EPS of €3.32.

PE Ratio

PROSUS has a trailing twelve months price to earnings ratio of 7.72. Meaning, the purchaser of the share is investing €7.72 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.98%.

Volatility

PROSUS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.51%, a negative 0.92%, and a positive 1.54%.

PROSUS’s highest amplitude of average volatility was 5.04% (last week), 1.68% (last month), and 1.54% (last quarter).

Yearly Top and Bottom Value

PROSUS’s stock is valued at €25.63 at 21:40 EST, way below its 52-week high of €36.41 and higher than its 52-week low of €25.49.

More news about PROSUS.

2. NORTHERN DRILLING (NODL.OL)

-13.11% Price Change

Northern Drilling Ltd. operates as an offshore drilling contractor to the oil and gas industry. The company primarily engages in acquiring and operating offshore drilling assets, as well as involved in drilling in ultra-deep water environments. Northern Drilling Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.

Oslo Børs Benchmark Index_GI ended the session with NORTHERN DRILLING dropping 13.11% to €1.16 on Monday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.22% to €1,295.42, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-5.8.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.22%.

Volume

Today’s last reported volume for NORTHERN DRILLING is 10380300 which is 247.82% above its average volume of 2984400.

More news about NORTHERN DRILLING.

3. POXEL (POXEL.PA)

-10.77% Price Change

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

CAC 40 ended the session with POXEL falling 10.77% to €0.58 on Monday, following the last session’s downward trend. CAC 40 fell 0.03% to €7,568.82, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, POXEL has a trailing twelve months EPS of €-1.08.

Yearly Top and Bottom Value

POXEL’s stock is valued at €0.58 at 21:40 EST, way below its 52-week high of €1.08 and way higher than its 52-week low of €0.30.

Volume

Today’s last reported volume for POXEL is 2821560 which is 1737.39% above its average volume of 153564.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1050.6%, now sitting on 1.55M for the twelve trailing months.

Moving Average

POXEL’s worth is way higher than its 50-day moving average of €0.37 and above its 200-day moving average of €0.55.

More news about POXEL.

4. SODITECH (SEC.PA)

-10% Price Change

Soditech SA engages in the integration of mechanical, thermal, and electronic sub-assemblies in space, research, and defense fields in France. It designs structural sub-assemblies and integrates optical and thermal equipment, such as OSRs, SSMs, heaters, and heat pipes; designs and manufactures multi-layer insulation products; and designs, manufactures, and tests space harnesses on instruments or platforms. The company also provides calculation services, such as static, dynamic, thermal, and thermoelastic; designs assembly tools; and designs and produces super insulating multi-layer mattresses for ultra-vacuum areas. In addition, it develops, qualifies, manufactures, and tests embedded cabinets; and designs, assembles, and tests racks and test equipment racks. The company was formerly known as Soditech Ingenierie SA. Soditech SA was founded in 1990 and is headquartered in Aix-en-Provence, France.

CAC 40 ended the session with SODITECH sliding 10% to €1.26 on Monday while CAC 40 fell 0.03% to €7,568.82.

Earnings Per Share

As for profitability, SODITECH has a trailing twelve months EPS of €0.07.

PE Ratio

SODITECH has a trailing twelve months price to earnings ratio of 18. Meaning, the purchaser of the share is investing €18 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.54%.

More news about SODITECH.

5. FAYENC.SARREGUEMI. (FAYE.PA)

-8% Price Change

Fayenceries de Sarreguemines, Digoin & Vitry-le-Francois Société Anonyme engages in ceramics business. The company provides bathroom fixtures and tiling, traditional and contemporary earthenware dishes, ceramic lighting fixtures, and hotel porcelain. It also exports its products. The company is headquartered in Paris, France.

CAC 40 ended the session with FAYENC.SARREGUEMI. sliding 8% to €18.40 on Monday, after five successive sessions in a row of losses. CAC 40 fell 0.03% to €7,568.82, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, FAYENC.SARREGUEMI. has a trailing twelve months EPS of €-1.6.

More news about FAYENC.SARREGUEMI..

6. CELYAD ONCOLOGY (CYAD.BR)

-6.22% Price Change

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with CELYAD ONCOLOGY falling 6.22% to €0.36 on Monday, following the last session’s downward trend. BEL 20 rose 1.66% to €3,679.69, following the last session’s upward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.36.

Volume

Today’s last reported volume for CELYAD ONCOLOGY is 99750 which is 109.79% above its average volume of 47546.

More news about CELYAD ONCOLOGY.

7. GUILLEMOT (GUI.PA)

-5.83% Price Change

Guillemot Corporation S.A. designs, manufactures, and sells interactive entertainment hardware and accessories in France, Germany, the United Kingdom, Spain, the United States, the Netherlands, Canada, Italy, China, Belgium, and Romania. It offers digital hardware, audio equipment, and peripherals under the Hercules brand name; PC and console gaming accessories under the Thrustmaster brand name; and DJ solutions for various connected devices under the DJUCED brand name. The company was founded in 1984 and is based in Carentoir, France.

CAC 40 ended the session with GUILLEMOT sliding 5.83% to €6.30 on Monday while CAC 40 dropped 0.03% to €7,568.82.

Earnings Per Share

As for profitability, GUILLEMOT has a trailing twelve months EPS of €-0.03.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.62%.

Volatility

GUILLEMOT’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.14%, a negative 0.60%, and a positive 1.93%.

GUILLEMOT’s highest amplitude of average volatility was 2.14% (last week), 1.43% (last month), and 1.93% (last quarter).

More news about GUILLEMOT.

8. BIOTALYS (BTLS.BR)

-5.62% Price Change

Biotalys NV, an agricultural technology company, discovers and develops novel biological products for the protection of food and crops. It primarily develops biofungicides, bioinsecticides, and biobactericides. The company was formerly known as Agrosavfe NV. Biotalys NV was incorporated in 2013 and is headquartered in Gent, Belgium.

BEL 20 ended the session with BIOTALYS dropping 5.62% to €4.70 on Monday, following the last session’s downward trend. BEL 20 rose 1.66% to €3,679.69, following the last session’s upward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, BIOTALYS has a trailing twelve months EPS of €-0.76.

Volatility

BIOTALYS’s last week, last month’s, and last quarter’s current intraday variation average was 10.80%, 5.61%, and 6.02%.

BIOTALYS’s highest amplitude of average volatility was 13.78% (last week), 11.07% (last month), and 6.02% (last quarter).

Volume

Today’s last reported volume for BIOTALYS is 31897 which is 32.11% below its average volume of 46984.

More news about BIOTALYS.

9. SEQUANA MEDICAL (SEQUA.BR)

-5.1% Price Change

Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

BEL 20 ended the session with SEQUANA MEDICAL sliding 5.1% to €3.72 on Monday while BEL 20 jumped 1.66% to €3,679.69.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.32.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -690.43%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SEQUANA MEDICAL’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

SEQUANA MEDICAL’s stock is valued at €3.72 at 21:40 EST, way below its 52-week high of €6.36 and way higher than its 52-week low of €2.22.

More news about SEQUANA MEDICAL.

10. HAVILA SHIPPING (HAVI.OL)

-4.45% Price Change

Havila Shipping ASA, together with its subsidiaries, engages in the shipping business. It manages and operates offshore service vessels primarily in Norway, the United Kingdom, Denmark, Belgium, the Netherlands, Iceland, Tunisia, the Marshall Islands, and the United States. The company operates a fleet of 17 vessels, including 2 anchor handling vessels, 11 platform supply vessels, 1 rescue recovery vessel, and 3 subsea vessels. Its anchor handling tug and supply vessels are used for moving rigs and putting out anchors, as well as for supply services; platform supply vessels are used to carry goods, water, drilling mud, chemicals, etc. to and from the offshore installations; subsea vessels are used for under water construction work, as well as for support for under water operations; and rescue recovery vessels are used to offer security services, such as oil spill preparedness, fire protection, rescue operation, and recovery at oil installations. The company was founded in 2003 and is headquartered in Fosnavåg, Norway. Havila Shipping ASA is a subsidiary of Havila Holding AS.

Oslo Børs Benchmark Index_GI ended the session with HAVILA SHIPPING dropping 4.45% to €5.37 on Monday while Oslo Børs Benchmark Index_GI rose 0.22% to €1,295.42.

Earnings Per Share

As for profitability, HAVILA SHIPPING has a trailing twelve months EPS of kr-2.45.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 345.66%.

More news about HAVILA SHIPPING.

Stay up to date with our winners and losers daily report